(Q37327047)

English

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

scientific article published on 14 May 2009

In more languages
default for all languages
No label defined

No description defined

Statements

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years (English)
Stephen Gitelman
William Hagopian
Peter Bianchine
Kasia Bourcier
Immune Tolerance Network ITN007AI Study Group

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit